To prove our hypothesis, we would need to prospectively compare the RVP in 2 groups of eyes with retinal vein occlusions, one receiving anti-VEGF injections and the other not receiving anti-VEGF injections. The gene discussed is VEGFA; the disease is retinal vein occlusion.